je.st
news
Tag: studies
AAMA Predicts Fenestration Industry Trends in New Market Studies
2014-05-01 06:00:00| Industrial Newsroom - All News for Today
AAMA has released AAMA 2013/2014 Study of the U.S. Market for Windows, Doors and Skylights. According to study, total conventional housing starts in 2013 experienced considerable increase and are forecasted to grow 20% in 2014. Conventional residential window applications increased by 15.8% to 43.9 million units, compared to 37.9 million units in 2011. Nonresidential market increased 9% in 2013 and is expected to continue to increase in 2014 throughout 2017.<br /> This story is related to the following:Trade Associations
Tags: market
industry
studies
trends
DOE to award up to $20M for further studies on methane hydrates; projects worth up to $80M
2014-04-14 12:30:21| Green Car Congress
Wind farms impact on house prices disputed in contradictory studies
2014-04-13 07:00:00| Climate Ark Climate Change & Global Warming Newsfeed
Blue and Green: Two separate studies looking at how wind farms affect house prices have drawn contrasting conclusions. The impact of wind farms on communities has been debated, with government proposing giving locals more say on developments. One of the pieces of research from the London School of Economics (LSE) suggests that wind farms can reduce house prices by as much as 12% when they are within 2km of the development. The report states, Wind farm developments reduce prices in locations where the turbines...
Tags: house
prices
studies
impact
Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Nave Patients with Genotype 1 Infection
2014-04-10 07:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Clinical Findings Support Advancement into Phase 3 Trials WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639Sarra Herzog, 201-669-6570orInvestors:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
results
studies
patients
Data From Phase 3 Pivotal Studies Show Amgen's Novel...
2014-03-30 17:13:28| Biotech - Topix.net
Data From Two Separate Phase 3 Studies of Evolocumab , a PCSK9 Inhibitor, Presented in Late-Breaking Clinical Trials Session at ACC.14 - Data Add to the Three Pivotal Studies Presented Yesterday /PRNewswire/ -- Amgen today announced new detailed data from two Phase 3 pivotal studies that showed treatment with its novel investigational ... (more)
Sites : [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] next »